Association between cytochrome P450 2C19 polymorphism and clinical outcomes in Chinese patients with coronary artery disease

作者：Chen, Mao; Liu, Xiao-Jing; Yan, Shao-Di; Peng, Yong; Chai, Hua; Li, Qiao; Wei, Jia-Fu; Xu, Yuan-Ning; Huang, De-Jia^*

来源：Atherosclerosis, 2012, 220(1): 168-171.

DOI：10.1016/j.atherosclerosis.2011.04.008

• CYP2C19*2
• Coronary artery disease
• Prognosis
• Chinese
• Polymorphism

Background: Cytochrome P450 (CYP)2C19 is expressed in vascular endothelium and metabolizes arachidonic acid to biologically active epoxyeicosatrienoic acids, which play a key role in regulating vascular tone. The aim of this study was to investigate whether the genetic functional variant 681G > A (*2) of cytochrome CYP2C19 is associated with adverse cardiovascular outcomes in Chinese patients with coronary artery disease (CAD). @@@ Methods: Between July 2008 and September 2009, 654 consecutive patients with CAD were enrolled in this study. All participants underwent CYP2C19 genotyping. The primary study endpoint was a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Secondary endpoints included the components of the primary endpoint, death from any cause, and recurrent revascularization. @@@ Results: The baseline characteristics were well-balanced between carriers (heterozygous *12, n = 291; homozygous *22, n = 57) and non-carriers (n = 306) of the CYP2C19*2 variant. During the follow-up period (11.42 +/- 4.23 months), the primary endpoint occurred more frequently in homozygous *22 than in non-carriers (n = 306) of CYP2C19*2 variant (12.28% versus 3.27%; adjusted hazard ratio [HR] = 5.191; 95% confidence interval [CI] = 1.936-13.917; P = 0.001); however, no such increase was evident in heterozygous *12 patients (4.12% versus 3.27%; adjusted HR = 1.208; 95% CI 0.517-2.822; P = 0.662). @@@ Conclusions: The homozygous CYP2C19*22 genotype is an independent determinant of adverse vascular events in Chinese patients with CAD.

• 出版日期2012-1
• 单位四川大学